Novartis' Leqvio显示,在将静脉注射器上的病人的LDL胆固醇降低59%方面,取得了显著成功。 Novartis' Leqvio shows significant success in lowering LDL cholesterol by 59% in patients on statins.

Novartis' Leqvio是一种RNA疗法,在降低已登上统计系统的病人的LDL胆固醇水平方面,早期取得了显著成功,在90天内达到目标水平的占85%。 Novartis' Leqvio, an RNA therapy, has shown significant early success in lowering LDL cholesterol levels in patients already on statins, with 85% reaching target levels within 90 days. 包括1 770名参与者的V-差异研究还发现,Leqvio一年后将肌肉疼痛和低胆固醇减少59%,大大超过安慰剂。 The V-DIFFERENCE study, involving 1,770 participants, also found that Leqvio reduces muscle pain and lowers cholesterol by 59% after a year, significantly more than a placebo. 在100多个国家中,Leqvis每年两次由保健服务提供者管理。 Approved in over 100 countries, Leqvis is administered twice yearly by healthcare providers.